Document is current
Any future updates will be listed below
-
Authors
Bernhardt, Alexander M.
Roeber, Sigrun
Ruf, Viktoria
Wlasich, Elisabeth
Weidinger, Endy
Longen, Sebastian
Trossbach, Svenja V.
Gnörich, Johannes
Brendel, Matthias
Herms, Jochen
Giese, Armin
Höglinger, Günter U.
Levin, Johannes
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Received: 28 March 2025
Accepted: 21 July 2025
First Online: 25 July 2025
Declarations
:
: This study was approved by our Institutional Review Board and patient gave consent.
: Alexander Bernhardt is inventor of a patent application related to a quantitative Lewy-fold specific alpha-synuclein seed amplification assay. Sebastian Longen reports full-time employment by AESKU.Diagnostics GmbH. In addition, he is inventor of a patent application related to a quantitative Lewy-fold specific alpha-synuclein seed amplification assay. Svenja V. Trossbach reports full-time employment by MODAG GmbH. In addition, she is inventor of a patent application related to a quantitative Lewy-fold specific alpha-synuclein seed amplification assay. Günter Höglinger is inventor of patents related to the treatment of synucleinopathies (United States Patent No.: US 10,918,628 B2, European Patent Patent No.: EP 17 787 904.6–1109 / 3 525 788). Armin Giese reports employment by and being a shareholder of MODAG GmbH. He is inventor of a patent application related to a quantitative Lewy-fold specific alpha-synuclein seed amplification assay. Johannes Levin reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA and Roche, consulting fees from Axon Neuroscience and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH. He is inventor of a patent application related to a quantitative Lewy-fold specific alpha-synuclein seed amplification assay. All other authors have no other competing interests to report.
